Igfbp7 Mouse Recombinant Protein

CAT#: TP727786

Recombinant Mouse IGF binding Protein 7/IGFBP-7 (C-6His)



Need it in bulk or customized?
Get a free quote

CNY 2,380.00


货期*
2周

规格
    • 10 ug

Product images

经常一起买 (1)
Goat Anti-IGFBP7 (aa145-159) Antibody
    • 100 ug

CNY 5,371.00

Specifications

Product Data
Species Mouse
Protein Source Human
Expression cDNA Clone or AA Sequence
Tag C-His
Buffer Lyophilized from a 0.2 um filtered solution of PBS, 150mM Nacl, pH 7.4.
Note Recombinant Mouse Insulin-like Growth Factor-binding Protein 7 is produced by our Mammalian expression system and the target gene encoding Ser26-Leu281 is expressed with a 6His tag at the C-terminus.
Stability 12 months from date of despatch
Reference Data
Locus ID 29817
UniProt ID Q61581
Summary Insulin-like growth factor-binding protein 7(IGFBP-7) is a secreted glycosylated protein that contains three protein domain modules. IGFBP7 contains an N-terminal IGFBP domain, followed by a Kazal-type serine proteinase inhibitor domain and a C-terminal immunoglobulin-like C2-type domain. Human and mouse IGFBP7 are highly homologous and share 94% aa sequence identity. It is expressed in many normal tissues and in cancer cells. It is abundantly expressed in high endothelial venules (HEVs) of blood vessels in the secondary lymphoid tissues. It binds IGF and insulin with very low affinity and has been shown to enhance the mitogenic actions of IGF and insulin. IGFBP7 also has IGF/insulin-independent activities. It interacts with heparan sulfate proteoglycans, type IV collagen, and specific chemokines. It supports weak cell adhesion, promotes cell spreading on type IV collagen, and stimulates the production of the potent vasodilator PGI2. It modulates tumor cell growth and has also been implicated in angiogenesis.
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Customer Reviews 
Loading...